TOP TEN perturbations for 1553508_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553508_at
Selected probe(set): 1562731_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553508_at (1562731_s_at) across 6673 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 12 (4 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):-2.7830372
Number of Samples:2 / 5
Experimental kidney transplantation study 12 (4 week)
CD4+ T-cell samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-2.7117214
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

kidney transplantation study 12 (2 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):-2.5719595
Number of Samples:6 / 5
Experimental kidney transplantation study 12 (2 week)
CD4+ T-cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

breast cancer study 24 / breast cancer study 22

Relative Expression (log2-ratio):-2.4399128
Number of Samples:10 / 10
Experimental breast cancer study 24
Freshly purified CD4+ tumor-infiltrating T cells derived from female primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information. The initial tissue dissociation was performed mechanically, without enzymatic digestion.
Control breast cancer study 22
Freshly purified CD4+ T cells from peripheral blood of female donors with primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-2.4299889
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

T-cell activation study 2 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-2.38622
Number of Samples:2 / 2
Experimental T-cell activation study 2
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days..
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

autologous nonmyeloablative hematopoietic stem cell transplantation study 1 (Diabetes type 1) / diabetes type 1 study 10 (pre-transplant)

Relative Expression (log2-ratio):-2.2553654
Number of Samples:9 / 9
Experimental autologous nonmyeloablative hematopoietic stem cell transplantation study 1 (Diabetes type 1)
Peripheral blood mononuclear cells (PBMC) derived from patients with type 1 diabetes six months after autologous nonmyeloablative hematopoietic stem cell transplantation (AHST). Transplantation was performed in normoglycemic patients treated for 2.0 ± 0.9 months with exogenous insulin. T1D diabetes was confirmed by fasting blood glucose level (FBG), postprandial blood glucose level (PBG), HbA1c test and by the presence of glutamic acid decarboxylase (GAD) auto antibodies. Patients were free of acute or chronic infection, had no familiar history of ketoacidosis, no organ dysfunction and were not pregnant.
Control diabetes type 1 study 10 (pre-transplant)
Peripheral blood mononuclear cells (PBMC) derived from patients with type 1 diabetes before autologous nonmyeloablative hematopoietic stem cell transplantation (AHST). PBMC samples were obtained from normoglycemic patients treated for 2.0 ± 0.9 months with exogenous insulin. T1D diabetes was confirmed by fasting blood glucose level (FBG), postprandial blood glucose level (PBG), HbA1c test and by the presence of glutamic acid decarboxylase (GAD) auto antibodies. Patients were free of acute or chronic infection, had no familiar history of ketoacidosis, no organ dysfunction and were not pregnant.

breast cancer study 24 / breast cancer study 23

Relative Expression (log2-ratio):-2.0877953
Number of Samples:10 / 10
Experimental breast cancer study 24
Freshly purified CD4+ tumor-infiltrating T cells derived from female primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information. The initial tissue dissociation was performed mechanically, without enzymatic digestion.
Control breast cancer study 23
Freshly purified CD4+ T cells from axillary lymph nodes of female donors with primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information. The initial tissue dissociation was performed mechanically, without enzymatic digestion.

kidney transplantation study 11 (2 week) / normal blood sample

Relative Expression (log2-ratio):-1.89079
Number of Samples:9 / 5
Experimental kidney transplantation study 11 (2 week)
Whole blood samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal blood sample
Blood samples derived from healthy control subjects.

kidney transplantation study 12 (12 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):-1.7911787
Number of Samples:9 / 5
Experimental kidney transplantation study 12 (12 week)
CD4+ T-cell samples derived from kidney transplant patients 12 weeks post-transplantation. Samples were collected 12 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.